| Cystadenocarcinoma studied in …STUDIED_INderived10 of 37show all (up to 200) |
|---|
| → studied in | NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01081262Phase 3 · active not recruiting Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Mucinous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Mucinous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03673124Phase 2 · active not recruiting Ribociclib and Letrozole Treatment in Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04458597NA · completed Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. · condition mapped PROBABILISTIC · 37 trials mapped (5 active) | — | — | Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05074472Phase 1/Phase 2 · completed A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Serous Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02059265Phase 2 · terminated Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 37 trials mapped (5 active) | — | — | Ovarian Clear Cell Cystadenocarcinoma | 1 | Observed | clinicaltrials | graph → |